Genome-wide/NN
Survey/NN
of/IN
Copy/NN
Number/NN
Variants/NNS
Associated/VBN
with/IN
Blood/NN
Pressure/NN
and/CC
Body/NN
Mass/NN
Index/NN
in/IN
a/DT
Korean/JJ
Population/NN
./.
====================
Hypertension/NN
is/VBZ
the/DT
major/JJ
factor/NN
of/IN
most/JJS
death/NN
and/CC
high/JJ
blood/NN
pressure/NN
(/(
BP/NN
)/)
can/MD
lead/VB
to/TO
stroke/JJ
,/,
myocardial/JJ
infarction/NN
and/CC
cardiac/JJ
failure/NN
./.
====================
Moreover/RB
,/,
hypertension/NN
is/VBZ
strongly/RB
correlated/VBD
with/IN
body/NN
mass/NN
index/NN
(/(
BMI/NN
)/)
./.
====================
Although/IN
the/DT
exact/JJ
causes/VBZ
of/IN
hypertension/NN
are/VBP
still/RB
unclear/JJ
,/,
some/DT
of/IN
genetic/JJ
loci/NNS
were/VBD
discovered/VBN
from/IN
genome-wide/NN
association/NN
study/NN
(/(
GWAS/NN
)/)
./.
====================
Therefore/RB
,/,
it/PRP
is/VBZ
essential/JJ
to/TO
study/VB
genetic/JJ
variation/NN
for/IN
finding/NN
more/RBR
genetic/JJ
factor/NN
affecting/VBG
hypertension/NN
./.
====================
The/DT
purpose/NN
of/IN
our/PRP$
study/NN
is/VBZ
to/TO
conduct/VB
a/DT
CNV/NN
association/NN
study/NN
for/IN
hypertension-related/JJ
traits/VBZ
,/,
BP/NN
and/CC
BMI/NN
,/,
in/IN
Korean/JJ
individuals/NNS
./.
====================
We/PRP
identified/VBD
2,206/CD
CNV/NN
regions/NNS
from/IN
3,274/CD
community-based/VBD
Korean/JJ
participants/NNS
using/VBG
the/DT
Affymetrix/JJ
Genome-Wide/NN
Human/JJ
SNP/NN
Array/NN
6.0/CD
platform/NN
and/CC
performed/VBN
a/DT
logistic/JJ
regression/NN
analysis/NN
of/IN
CNVs/NNS
with/IN
two/CD
hypertension-related/JJ
traits/VBZ
,/,
BP/NN
and/CC
BMI/NN
./.
====================
Moreover/RB
,/,
the/DT
4,692/CD
participants/NNS
in/IN
an/DT
independent/JJ
cohort/NN
were/VBD
selected/VBN
for/IN
respective/JJ
replication/NN
analyses/NNS
./.
====================
GWAS/NN
of/IN
CNV/NN
identified/VBN
two/CD
loci/NNS
encompassing/VBG
previously/RB
known/VBN
hypertension-related/JJ
genes/NNS
:/:
LPA/NN
(/(
lipoprotein/NN
)/)
on/IN
6q26/NN
,/,
and/CC
JAK2/NN
(/(
Janus/NN
kinase/NN
2/CD
)/)
on/IN
9p24/NN
,/,
with/IN
suggestive/JJ
pvalues/NNS
(/(
0.0334/CD
for/IN
LPA/NN
and/CC
0.0305/CD
for/IN
JAK2/NN
)/)
./.
====================
These/DT
two/CD
positive/JJ
findings/NNS
,/,
however/RB
,/,
were/VBD
not/RB
evaluated/VBN
in/IN
the/DT
replication/NN
stage/NN
./.
====================
Our/PRP$
result/NN
confirmed/VBD
the/DT
conclusion/NN
of/IN
CNV/NN
study/NN
from/IN
the/DT
WTCCC/NN
suggesting/VBG
weak/JJ
association/NN
with/IN
common/JJ
diseases/NNS
./.
====================
This/DT
is/VBZ
the/DT
first/JJ
study/NN
of/IN
CNV/NN
association/NN
study/NN
with/IN
BP/NN
and/CC
BMI/NN
in/IN
Korean/JJ
population/NN
and/CC
it/PRP
provides/VBZ
a/DT
state/NN
of/IN
CNV/NN
association/NN
study/NN
with/IN
common/JJ
human/JJ
diseases/NNS
using/VBG
SNP/NN
array/NN
./.
====================
Keywords/IN
:/:
copy/NN
number/NN
variation/NN
,/,
hypertensionrelated/JJ
traits/VBZ
,/,
BMI/NNP
,/,
blood/NN
pressure/NN
,/,
genomewide/NN
association/NN
studyCopy/NN
number/NN
variation/NN
(/(
CNV/NN
)/)
is/VBZ
defined/VBN
as/IN
a/DT
loss/NN
or/CC
gain/NN
of/IN
long/JJ
segments/NNS
of/IN
DNA/NN
,/,
and/CC
it/PRP
is/VBZ
relatively/RB
common/JJ
in/IN
the/DT
human/JJ
genome/NN
(/(
Freeman/JJ
et/FW
al./FW
,/,
2006/CD
;/:
McCarroll/NNP
et/FW
al./FW
,/,
2008/CD
;/:
Redon/NN
et/FW
al./FW
,/,
2006/CD
)/)
./.
====================
Because/IN
some/DT
chromosomal/JJ
duplications/NNS
and/CC
deletions/NNS
are/VBP
known/VBN
to/TO
be/VB
associated/VBN
with/IN
disease/NN
susceptibility/NN
and/CC
gene/NN
dosage/NN
,/,
CNVs/NNS
are/VBP
considered/VBN
major/JJ
sources/NNS
of/IN
genomic/JJ
variation/NN
along/IN
with/IN
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
(/(
Freeman/JJ
et/FW
al./FW
,/,
2006/CD
;/:
McCarroll/NNP
et/FW
al./FW
,/,
2008/CD
)/)
./.
====================
A/DT
CNV/NN
study/NN
has/VBZ
reported/VBN
populationdependent/JJ
CNVs/NNS
that/DT
inconsistently/RB
occur/VBP
between/IN
ethnic/JJ
groups/NNS
(/(
Redon/NN
et/FW
al./FW
,/,
2006/CD
)/)
./.
====================
To/TO
date/NN
,/,
a/DT
number/NN
of/IN
genomic/JJ
variants/NNS
associating/VBG
SNP/NN
loci/NNS
with/IN
susceptibility/NN
to/TO
common/JJ
complex/NN
human/JJ
diseases/NNS
have/VBP
been/VBN
identified/VBN
through/IN
genomewide/JJ
association/NN
studies/NNS
(/(
GWASs/NNS
)/)
(/(
The/DT
WTCCC/NN
,/,
2007/CD
;/:
Estivill/RB
and/CC
Armengol/NN
,/,
2007/CD
;/:
Hong/RB
et/FW
al./FW
,/,
2009/CD
;/:
Cho/NNP
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
Although/IN
some/DT
CNV/NN
studies/NNS
have/VBP
also/RB
reported/VBD
associations/NNS
with/IN
several/JJ
complex/NN
disorders/NNS
,/,
the/DT
corresponding/JJ
CNV/NN
data/NNS
are/VBP
scarce/NN
compared/VBN
with/IN
SNP/NN
data/NNS
./.
====================
Moreover/RB
,/,
previous/JJ
GWASs/NNS
reported/VBD
associations/NNS
of/IN
SNPs/NNS
with/IN
anthropometric/JJ
traits/VBZ
including/VBG
blood/NN
pressure/NN
(/(
BP/NN
)/)
and/CC
body/NN
mass/NN
index/NN
(/(
BMI/NN
)/)
in/IN
the/DT
Korean/JJ
population/NN
(/(
Hong/JJ
et/FW
al./FW
,/,
2009/CD
;/:
Cho/NNP
et/FW
al./FW
,/,
2009/CD
)/)
,/,
but/CC
no/DT
CNV/NN
association/NN
studies/NNS
with/IN
these/DT
traits/NNS
have/VBP
been/VBN
reported/VBN
./.
====================
The/DT
aims/NNS
of/IN
our/PRP$
current/JJ
study/NN
were/VBD
as/IN
follows/VBZ
:/:
1/CD
)/)
discover/RB
Korean/JJ
CNV/NN
regions/NNS
(/(
CNVRs/NNS
)/)
in/IN
largescale/JJ
cohort/JJ
samples/NNS
;/:
2/CD
)/)
examine/VBP
additional/JJ
loci/NNS
that/IN
may/MD
be/VB
associated/VBN
with/IN
hypertensionrelated/JJ
traits/VBZ
;/:
3/LS
)/)
compare/VBP
association/NN
results/VBZ
of/IN
CNVs/NNS
with/IN
those/DT
of/IN
previously/RB
known/VBN
risk/NN
loci/NNS
./.
====================
Toward/RB
these/DT
goals/NNS
,/,
we/PRP
performed/VBD
a/DT
three/CD
stage/NN
analysis/NN
./.
====================
In/IN
the/DT
first/JJ
stage/NN
,/,
we/PRP
conducted/VBD
a/DT
genomewide/JJ
survey/NN
of/IN
CNVs/NNS
in/IN
3,274/CD
healthy/JJ
Korean/JJ
participants/NNS
as/IN
part/NN
of/IN
the/DT
Korean/JJ
Genome/NN
Epidemiology/JJ
Study/NN
(/(
KoGES/NN
)/)
using/VBG
the/DT
Affymetrix/JJ
GenomeWide/NN
Human/JJ
SNP/NN
Array/NN
6.0/CD
platform/NN
./.
====================
Using/VBG
stringent/JJ
quality/NN
control/NN
,/,
we/PRP
ascertained/VBD
2,206/CD
CNVRs/NNS
./.
====================
In/IN
the/DT
second/JJ
stage/NN
,/,
we/PRP
carried/VBD
out/RP
a/DT
logistic/JJ
regression/NN
analysis/NN
of/IN
CNVs/NNS
with/IN
two/CD
hypertensionrelated/JJ
traits/VBZ
,/,
BP/NN
and/CC
BMI/NN
./.
====================
Of/IN
the/DT
3,274/NN
participants/NNS
in/IN
this/DT
study/NN
,/,
1,725/CD
(/(
602/CD
cases/NNS
,/,
1,123/CD
controls/NNS
)/)
were/VBD
selected/VBN
for/IN
association/NN
analysis/NN
with/IN
BP/NN
;/:
for/IN
BMI/NN
,/,
3,212/NN
participants/NNS
(/(
1,112/CD
cases/NNS
,/,
2,100/CD
controls/NNS
)/)
were/VBD
similarly/RB
selected/VBN
./.
====================
In/IN
the/DT
third/JJ
stage/NN
,/,
of/IN
the/DT
4,692/CD
participants/NNS
genotyped/VBD
with/IN
the/DT
Affymetrix/JJ
Genome-Wide/NN
Human/JJ
SNP/NN
array/NN
5.0/CD
platform/VBP
in/IN
an/DT
independent/JJ
cohort/NN
,/,
we/PRP
selected/VBD
3,507/CD
(/(
1,561/CD
cases/NNS
,/,
1,946/CD
controls/VBZ
)/)
and/CC
4,592/CD
(/(
2,095/CD
cases/NNS
,/,
2,497/CD
controls/VBZ
)/)
participants/NNS
for/IN
inclusion/NN
in/IN
the/DT
respective/JJ
replication/NN
analysis/NN
datasets/NNS
for/IN
these/DT
two/CD
CNVRs/NNS
./.
====================
In/IN
conclusion/NN
,/,
our/PRP$
result/NN
is/VBZ
consistent/JJ
with/IN
that/DT
of/IN
the/DT
Wellcome/JJ
Trust/NNP
Case/NN
Control/NN
Consortium/NN
(/(
WTCCC/NN
)/)
CNV/NN
study/NN
(/(
2010/CD
)/)
./.
====================
Thus/RB
,/,
our/PRP$
result/NN
confirmed/VBD
the/DT
conclusion/NN
of/IN
WTCCC/NN
CNV/NN
study/NN
suggesting/VBG
weak/JJ
association/NN
with/IN
complex/NN
traits/VBZ
./.
====================
Although/IN
we/PRP
also/RB
found/VBD
no/DT
Asianspecific/JJ
CNVs/NNS
associated/VBN
with/IN
hypertension-related/JJ
traits/VBZ
,/,
our/PRP$
study/NN
is/VBZ
the/DT
first/JJ
to/TO
examine/VB
the/DT
contribution/NN
of/IN
CNVs/NNS
to/TO
common/JJ
complex/NN
diseases/NNS
in/IN
a/DT
Korean/JJ
population/NN
and/CC
will/MD
provide/VB
new/JJ
insight/NN
into/IN
the/DT
genetics/NNS
associated/VBN
with/IN
complex/NN
traits/VBZ
having/VBG
underlying/VBG
CNVs/NNS
in/IN
the/DT
Korean/JJ
population/NN
./.
====================
Study/NN
participants/NNS
were/VBD
enrolled/VBN
from/IN
a/DT
population/NN
based/VBN
cohort/VBP
called/VBN
the/DT
Health/NN
Examinee/NN
(/(
HEXA/NN
)/)
cohort/VBP
,/,
which/WDT
is/VBZ
a/DT
part/NN
of/IN
KoGES/NN
./.
====================
DNA/NN
was/VBD
extracted/VBN
from/IN
peripheral/JJ
blood/NN
with/IN
informed/VBN
consent/NN
./.
====================
Through/IN
each/DT
step/NN
of/IN
SNP/NN
quality/NN
control/NN
procedures/NNS
(/(
sample/NN
call/JJ
rate/NN
≥95/CD
%/NN
,/,
gender/NN
inconsistency/NN
check/NN
,/,
exclusion/NN
of/IN
cancer/NN
patients/NNS
,/,
population/NN
stratification/NN
check/NN
,/,
etc/JJ
./.
====================
)/)
,/,
the/DT
3,703/CD
healthy/JJ
individuals/NNS
(/(
aged/JJ
between/IN
40/CD
and/CC
70/CD
years/NNS
)/)
were/VBD
genotyped/VBN
on/IN
the/DT
Affymetrix/JJ
Human/JJ
GenomeWide/NN
SNP/NN
array/NN
6.0/CD
./.
====================
This/DT
dataset/NN
was/VBD
composed/VBN
of/IN
44.6/CD
%/NN
male/JJ
and/CC
55.4/CD
%/NN
female/JJ
samples/NNS
./.
====================
Files/NNS
with/IN
raw/NN
signal/NN
intensity/NN
(/(
CEL/NN
files/NNS
)/)
from/IN
the/DT
3,703/CD
samples/NNS
were/VBD
converted/VBN
to/TO
normalized/VBN
log/NN
R/NN
intensity/NN
ratios/NNS
./.
====================
Pooled/JJ
referenceFor/IN
the/DT
Affymetrix/JJ
Genome-Wide/NN
Human/JJ
SNP/NN
array/NN
6.0/CD
,/,
pre-processing/VBG
procedures/NNS
(/(
background/NN
subtraction/NN
,/,
normalization/NN
,/,
summarization/NN
of/IN
probe/NN
set/NN
)/)
were/VBD
performed/VBN
with/IN
the/DT
apt-probeset-summarize/VBP
application/NN
(/(
Affymetrix/JJ
Power/JJR
Tools/NNS
;/:
http/RB
:/:
//www/JJ
./.
====================
affymetrix/IN
./.
====================
com/partners_programs/programs/developer/tools/powertools/NNS
./.
====================
affx/IN
)/)
./.
====================
After/IN
pre-processing/VBG
procedures/NNS
,/,
the/DT
signal/NN
intensity/NN
ratio/NN
between/IN
the/DT
test/NN
and/CC
the/DT
reference/NN
sample/NN
of/IN
each/DT
probe/NN
was/VBD
transformed/VBN
to/TO
log2/NN
scale/NN
with/IN
the/DT
chromosomal/JJ
coordinate/JJ
of/IN
the/DT
probes/NNS
(/(
UCSC/NN
version/NN
hg18//RB
NCBI/NN
Build/JJ
36/CD
)/)
./.
====================
The/DT
technical/JJ
artifact/NN
,/,
spatial/JJ
autocorrelation/NN
or/CC
‘/JJ
wave/NN
’/CD
,/,
which/WDT
occurs/VBZ
in/IN
a/DT
large/JJ
dataset/NN
used/VBN
to/TO
determine/VB
the/DT
location/NN
of/IN
CNV/NN
across/IN
the/DT
genome/NN
,/,
were/VBD
removed/VBN
by/IN
WaveNorm/NN
software/RB
(/(
Marioni/NNP
et/FW
al./FW
,/,
2007/CD
)/)
./.
====================
DNA/NN
from/IN
a/DT
single/JJ
individual/JJ
such/JJ
as/IN
NA10851/NN
or/CC
NA15510/NN
was/VBD
used/VBN
for/IN
CNV/NN
discovery/NN
in/IN
some/DT
reported/VBN
CNV/NN
analyses/NNS
(/(
Redon/NN
et/FW
al./FW
,/,
2006/CD
;/:
Komura/NN
et/FW
al./FW
,/,
2006/CD
;/:
Olsen/NNP
and/CC
Venkatraman/JJ
,/,
2004/CD
)/)
./.
====================
However/RB
,/,
the/DT
probability/NN
that/DT
the/DT
reference/NN
CNV/NN
region/NN
was/VBD
homozygously/RB
deleted/VBN
may/MD
lead/VB
to/TO
detection/NN
of/IN
falsepositive/JJ
CNVs/NNS
(/(
Marioni/NNP
et/FW
al./FW
,/,
2007/CD
;/:
Komura/NN
et/FW
al./FW
,/,
2006/CD
)/)
./.
====================
Therefore/RB
,/,
we/PRP
assumed/VBD
that/IN
the/DT
reference/NN
effect/NN
of/IN
a/DT
homozygously/RB
deleted/VBN
CNV/NN
region/NN
could/MD
be/VB
minimized/VBN
by/IN
using/VBG
the/DT
pooled/JJ
reference/VBP
signal/NN
intensity/NN
./.
====================
Finally/RB
,/,
we/PRP
used/VBD
the/DT
average/NN
intensity/NN
of/IN
100/CD
samples/NNS
that/DT
were/VBD
randomly/RB
selected/VBN
from/IN
among/IN
3,703/CD
cohort/NN
participants/NNS
rather/RB
than/IN
a/DT
single/JJ
individual/JJ
’/NN
s/NNS
intensity/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
CNV/NN
detectionTo/TO
increase/VBP
the/DT
robustness/JJ
of/IN
CNV/NN
detection/NN
,/,
two/CD
different/JJ
algorithms/NNS
,/,
DNAcopy/JJ
(/(
Olsen/NNP
and/CC
Venkatraman/JJ
,/,
2004/CD
)/)
and/CC
the/DT
Genome/NN
Alteration/NN
Detection/NN
Analysis/NN
(/(
GADA/NN
)/)
(/(
PiqueRegi/NN
et/FW
al./FW
,/,
2008/CD
)/)
,/,
were/VBD
used/VBN
./.
====================
To/TO
define/VB
the/DT
threshold/NN
,/,
different/JJ
threshold/NN
Ts/NNS
were/VBD
tested/VBN
from/IN
3/CD
to/TO
4.5/CD
./.
====================
Finally/RB
,/,
we/PRP
ran/VBD
DNAcopy/NN
by/IN
default/NN
and/CC
the/DT
GADA/NN
R/NN
package/NN
with/IN
T=4.5/CD
,/,
α=0.2/CD
,/,
and/CC
MinSegLen=6/NN
on/IN
the/DT
3,603/CD
individuals/NNS
(/(
excluding/VBG
100/CD
samples/NNS
for/IN
pooled/JJ
reference/VBP
)/)
./.
====================
In/IN
addition/NN
,/,
the/DT
average/NN
log2/NN
ratio/NN
for/IN
defining/VBG
CNV/NN
segments/NNS
was/VBD
set/NN
to±0.3/CD
./.
====================
Eventually/RB
,/,
we/PRP
chose/VBP
3,274/CD
samples/NNS
with/IN
both/DT
a/DT
median/JJ
of/IN
the/DT
absolute/JJ
value/NN
of/IN
all/DT
pairwise/JJ
differences/NNS
(/(
MAPD/NN
)/)
of/IN
＜0.3/CD
and/CC
the/DT
number/NN
of/IN
CNV/NN
segments/NNS
within/IN
the/DT
outlier/NN
detection/NN
limits/VBZ
(/(
Q1−1.5×IQR∼Q3+1.5×IQR/NN
)/)
(/(
see/VB
supplementary/JJ
methods/NNS
:/:
participant/JJ
pruning/VBG
;/:
supplementary/RB
Fig/NN
./.
====================
S2/NN
)/)
./.
====================
After/IN
subsequent/JJ
stringent/JJ
qualitycontrol/JJ
processes/NNS
,/,
2,206/CD
CNVRs/NNS
were/VBD
used/VBN
for/IN
further/JJ
studies/NNS
(/(
see/VB
supplementary/JJ
methods/NNS
:/:
CNV/NN
segment/NN
selection/NN
and/CC
CNVR/NN
;/:
supplementary/RB
Fig/NN
./.
====================
S1/NN
;/:
supplementary/VBP
Fig/NN
./.
====================
S3/NN
)/)
./.
====================
Disease/NN
association/NN
stage/NN
The/DT
basic/JJ
characteristics/NNS
of/IN
the/DT
participants/NNS
are/VBP
listed/VBN
in/IN
Table/JJ
1/CD
./.
====================
In/IN
this/DT
study/NN
,/,
systolic/JJ
blood/NN
pressure/NN
(/(
SBP/NN
)/)
and/CC
diastolic/JJ
blood/NN
pressure/NN
(/(
DBP/NN
)/)
were/VBD
taken/VBN
from/IN
the/DT
averages/NNS
of/IN
three/CD
recumbent/JJ
measurements/NNS
./.
====================
The/DT
602/CD
cases/NNS
were/VBD
defined/VBN
as/IN
having/VBG
SBP≥140/NN
mmHg/NN
or/CC
DBP/NN
≥90/CD
mmHg/NN
./.
====================
The/DT
1,123/CD
controls/NNS
were/VBD
defined/VBN
as/IN
having/VBG
SBP＜120/NN
mmHg/NN
and/CC
DBP＜80/CD
mmHg/NN
./.
====================
Average/DT
SBP/NN
and/CC
DBP/NN
of/IN
study/NN
participants/NNS
were/VBD
119.15±18.25/CD
and/CC
75.85±12.70/CD
mmHg/NN
,/,
respectively/RB
(/(
Table/JJ
1/CD
)/)
./.
====================
In/IN
addition/NN
,/,
we/PRP
defined/VBD
BMI/NN
as/IN
the/DT
individual/JJ
’/CD
s/NNS
weight/NN
in/IN
kilograms/NNS
divided/VBN
by/IN
the/DT
height/NN
in/IN
meters/NNS
squared/VBD
,/,
according/VBG
to/TO
the/DT
World/NN
Health/NN
Organization/NN
BMI/NN
thresholds/NNS
./.
====================
The/DT
1,112/NN
cases/NNS
were/VBD
defined/VBN
as/IN
having/VBG
a/DT
BMI≥25/NN
kg/m2/NN
,/,
and/CC
the/DT
2,100/CD
controls/NNS
were/VBD
defined/VBN
having/VBG
18.5≤BMI＜25/CD
kg/m2/NN
./.
====================
The/DT
average/JJ
BMI/NN
of/IN
all/DT
study/NN
participants/NNS
was/VBD
24.08±2.76/CD
(/(
Table/JJ
1/CD
)/)
./.
====================
For/IN
the/DT
regression/NN
analysis/NN
,/,
copy/NN
number/NN
deletion/NN
,/,
normal/JJ
and/CC
duplication/NN
were/VBD
encoded/VBN
to/TO
−1/CD
,/,
0/CD
and/CC
+1/CD
,/,
respectively/RB
./.
====================
Logistic/JJ
regression/NN
analyses/NNS
were/VBD
conducted/VBN
by/IN
SAS/NN
software/JJ
,/,
and/CC
all/DT
models/NNS
were/VBD
adjusted/VBN
for/IN
gender/NN
and/CC
age/NN
./.
====================
Replication/NN
stageTwo/CD
positive/JJ
CNV/NN
loci/NNS
were/VBD
evaluated/VBN
in/IN
an/DT
independent/JJ
cohort/NN
./.
====================
For/IN
replication/NN
analysis/NN
,/,
we/PRP
used/VBD
4,692/CD
participants/NNS
from/IN
the/DT
AnsungAnsan/NN
cohort/NN
,/,
which/WDT
is/VBZ
also/RB
a/DT
part/NN
of/IN
KoGES/NN
./.
====================
These/DT
participants/NNS
were/VBD
genotyped/VBN
with/IN
the/DT
Affymetrix/JJ
GenomeWide/NN
Human/JJ
SNP/NN
Array/NN
5.0/CD
and/CC
passed/VBN
each/DT
step/NN
of/IN
the/DT
SNP/NN
quality/NN
control/NN
procedures/NNS
(/(
sample/JJ
call/JJ
rate/NN
≥96/CD
%/NN
,/,
heterozygosity/NN
≥30/CD
%/NN
,/,
gender/RB
inconsistency/NN
check/NN
,/,
exclusion/NN
of/IN
patients/NNS
with/IN
tumors/NNS
,/,
and/CC
population/NN
stratification/NN
check/NN
)/)
./.
====================
Using/VBG
the/DT
same/JJ
definition/NN
as/IN
for/IN
the/DT
association/NN
stage/NN
,/,
we/PRP
selected/VBD
3,507/CD
(/(
1,561/CD
cases/NNS
,/,
1,946/CD
controls/NNS
)/)
and/CC
4,592/CD
(/(
2,095/CD
cases/NNS
,/,
2,497/CD
controls/NNS
)/)
individuals/NNS
for/IN
BP/NN
and/CC
BMI/NN
,/,
respectively/RB
./.
====================
The/DT
DNAcopy/JJ
was/VBD
used/VBN
for/IN
CNV/NN
detection/NN
./.
====================
Logistic/JJ
regression/NN
analyses/NNS
were/VBD
also/RB
conducted/VBD
./.
====================
As/IN
mentioned/VBN
above/JJ
,/,
145,689/CD
of/IN
163,829/CD
CNV/NN
segments/NNS
were/VBD
selected/VBN
for/IN
further/JJ
study/NN
./.
====================
These/DT
segments/NNS
consisted/VBD
of/IN
53,817/CD
gains/NNS
and/CC
91,872/CD
losses/NNS
./.
====================
Finally/RB
,/,
2,206/CD
CNVRs/NNS
were/VBD
defined/VBN
from/IN
among/IN
these/DT
CNV/NN
segments/NNS
./.
====================
Of/IN
these/DT
CNVRs/NNS
,/,
69.2/CD
%/NN
(/(
1,527/NN
of/IN
2,206/CD
)/)
overlapped/VBD
by/IN
≥1/CD
bp/NN
with/IN
14,411/CD
CNVRs/NNS
in/IN
the/DT
Database/NN
of/IN
Genomic/JJ
Variants/NNS
(/(
DGVs/NNS
;/:
http/RB
:/:
//projects/NNS
./.
====================
tcag/DT
./.
====================
ca/variation//RB
)/)
./.
====================
Conversely/RB
,/,
10.7/CD
%/NN
(/(
1,538/CD
of/IN
15,411/CD
)/)
of/IN
CNVRs/NNS
in/IN
DGV/NN
matched/VBN
with/IN
our/PRP$
results/NNS
(/(
see/VB
supplementary/JJ
Fig/NN
./.
====================
S4/NN
)/)
./.
====================
The/DT
average/JJ
and/CC
median/JJ
length/NN
of/IN
all/DT
CNVRs/NNS
was/VBD
72.1/CD
kb/NN
and/CC
23.0/CD
kb/NN
,/,
respectively/RB
(/(
see/VB
supplementary/JJ
Table/JJ
1/CD
)/)
./.
====================
Moreover/RB
,/,
an/DT
average/NN
of/IN
44.5/CD
CNV/NN
segments/NNS
was/VBD
found/VBN
in/IN
each/DT
individual/JJ
(/(
see/VB
supplementary/JJ
Fig/NN
./.
====================
S5/NN
)/)
./.
====================
We/PRP
examined/VBD
the/DT
distribution/NN
of/IN
the/DT
2,206/CD
CNVRs/NNS
by/IN
frequency/NN
of/IN
occurrence/NN
./.
====================
Fig/NN
./.
====================
2A/NN
and/CC
Fig/NN
./.
====================
2B/NN
show/VBP
the/DT
distribution/NN
of/IN
CNVRs/NNS
with/IN
a/DT
frequency/NN
of/IN
more/RBR
than/IN
1/CD
%/NN
and/CC
less/RBR
than/IN
1/CD
%/NN
,/,
respectively/RB
./.
====================
Among/IN
the/DT
CNVRs/NNS
with/IN
a/DT
frequency/NN
of/IN
＞1/NN
%/NN
,/,
most/JJS
of/IN
the/DT
detected/VBN
CNVRs/NNS
had/VBD
a/DT
frequency/NN
of/IN
1∼5/CD
%/NN
(/(
Fig/NN
./.
====================
2A/NN
)/)
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
because/IN
we/PRP
excluded/VBD
all/DT
singleton/JJ
CNV/NN
segments/NNS
as/IN
well/RB
as/IN
some/DT
of/IN
the/DT
doubletons/NNS
and/CC
tripletons/NNS
according/VBG
to/TO
the/DT
stringent/JJ
rule/JJ
(/(
see/VB
supplementary/JJ
methods/NNS
:/:
CNV/NN
region/NN
)/)
,/,
most/JJS
CNVRs/NNS
with/IN
a/DT
frequency/NN
of/IN
＜1/NN
%/NN
were/VBD
included/VBN
in/IN
a/DT
frequency/NN
range/NN
of/IN
0.1∼0.5/CD
%/NN
(/(
Fig/NN
./.
====================
2B/NN
)/)
./.
====================
The/DT
number/NN
of/IN
CNVRs/NNS
with/IN
a/DT
frequency/NN
of/IN
＜1/NN
%/NN
was/VBD
approximately/RB
four/CD
times/NNS
as/IN
many/JJ
as/IN
the/DT
number/NN
with/IN
a/DT
frequency/NN
of/IN
＞1/NN
%/NN
(/(
Fig/NN
./.
====================
2C/NN
)/)
./.
====================
We/PRP
surveyed/VBD
RefSeq/NN
genes/NNS
partially/RB
or/CC
entirely/RB
harboring/VBG
2,206/CD
CNVRs/NNS
and/CC
found/VBD
1,556/CD
genes/NNS
./.
====================
The/DT
PANTHER/NN
classification/NN
system/NN
(/(
Thomas/NNS
et/FW
al./FW
,/,
2003/CD
)/)
was/VBD
used/VBN
to/TO
assess/VB
the/DT
functional/JJ
implications/NNS
of/IN
these/DT
CNVRs/NNS
./.
====================
PANTHER/NN
results/NNS
showed/VBD
genes/NNS
involved/VBN
in/IN
metabolic/JJ
processes/NNS
,/,
cellular/JJ
processes/NNS
and/CC
communication/NN
,/,
immune/JJ
system/NN
processes/NNS
,/,
etc/JJ
(/(
see/VB
supplementary/JJ
Table/JJ
2/CD
)/)
./.
====================
We/PRP
tested/VBD
the/DT
association/NN
between/IN
CNVs/NNS
and/CC
two/CD
kinds/NNS
of/IN
applicable/JJ
anthropometry/NN
traits/VBZ
,/,
BP/NN
and/CC
BMI/NN
./.
====================
In/IN
all/DT
,/,
14/CD
CNVRs/NNS
that/DT
overlapped/VBD
by/IN
≥1/CD
bp/NN
with/IN
18/CD
genes/NNS
were/VBD
significantly/RB
associated/VBN
with/IN
BP/NN
and/CC
hypertension/NN
with/IN
pvalue＜0.05/NN
./.
====================
Regarding/VBG
an/DT
association/NN
between/IN
BMI/NN
and/CC
CNV/NN
,/,
14/CD
CNVRs/NNS
that/DT
overlapped/VBD
by/IN
≥1/CD
bp/NN
with/IN
13/CD
genes/NNS
showed/VBD
association/NN
,/,
with/IN
pvalue＜0.05/NN
(/(
Table/JJ
2/CD
)/)
./.
====================
To/TO
compare/VB
all/DT
31/CD
genes/NNS
with/IN
previously/RB
reported/VBD
genetic/JJ
associations/NNS
,/,
we/PRP
used/VBD
Genopedia/NN
in/IN
HuGE/NN
Navigator/NN
(/(
Yu/NNP
et/FW
al./FW
,/,
2008/CD
)/)
./.
====================
Two/CD
CNVRs/NNS
encompassing/VBG
known/VBN
hypertensionrelated/JJ
genes/NNS
,/,
LPA/NN
and/CC
JAK2/NN
,/,
were/VBD
observed/VBN
with/IN
suggestive/JJ
pvalues/NNS
(/(
0.0334/CD
for/IN
LPA/NN
and/CC
0.0305/CD
for/IN
JAK2/NN
)/)
./.
====================
CNV/NN
loci/NNS
overlapping/VBG
LPA/NN
were/VBD
registered/VBN
in/IN
DGV/NN
./.
====================
These/DT
two/CD
CNVRs/NNS
were/VBD
selected/VBN
for/IN
further/JJ
replication/NN
studies/NNS
./.
====================
For/IN
the/DT
replication/NN
stage/NN
,/,
CNV/NN
loci/NNS
overlapping/VBG
LPA/NN
and/CC
JAK2/NN
were/VBD
observed/VBN
with/IN
nonsignificant/JJ
pvalues/NNS
of/IN
0.8687/CD
(/(
odds/NNS
ratio/NN
:/:
1.041/CD
,/,
95/CD
%/NN
confidence/NN
interval/JJ
:/:
0.644∼1.684/CD
)/)
and/CC
0.2782/CD
(/(
odds/NNS
ratio/NN
:/:
0.775/CD
,/,
95/CD
%/NN
confidence/NN
interval/JJ
:/:
0.489∼1.229/CD
)/)
,/,
respectively/RB
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
Hypertension/NN
refers/VBZ
to/TO
a/DT
clinically/RB
significant/JJ
increase/NN
in/IN
BP/NN
,/,
and/CC
it/PRP
is/VBZ
an/DT
important/JJ
risk/NN
factor/NN
for/IN
cardiovascular/JJ
disease/NN
;/:
further/RB
,/,
excess/RB
body/NN
weight/NN
is/VBZ
a/DT
major/JJ
risk/NN
factor/NN
for/IN
hypertension/NN
(/(
The/DT
WTCCC/NN
,/,
2007/CD
)/)
./.
====================
Development/NN
of/IN
hypertension/NN
,/,
however/RB
,/,
hypertension/NN
has/VBZ
a/DT
multifactorial/JJ
etiology/NN
,/,
including/VBG
both/CC
genetic/JJ
and/CC
environmental/JJ
factors/NNS
./.
====================
Therefore/RB
,/,
the/DT
distinctive/JJ
causes/VBZ
and/CC
factors/NNS
of/IN
hypertension/NN
are/VBP
still/RB
not/RB
fully/RB
understood/VBN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
found/VBD
that/IN
two/CD
CNVRs/NNS
overlapped/VBD
with/IN
previously/RB
known/VBN
risk/NN
loci/NNS
,/,
namely/RB
LPA/NN
on/IN
6q26/NN
and/CC
JAK2/NN
on/IN
9p24/NN
./.
====================
Some/DT
association/NN
studies/NNS
have/VBP
been/VBN
reported/VBN
regarding/VBG
these/DT
loci/NNS
./.
====================
For/IN
example/NN
,/,
common/JJ
variants/NNS
in/IN
LPA/NN
are/VBP
associated/VBN
with/IN
myocardial/JJ
infarction/NN
(/(
Deo/NNP
et/FW
al./FW
,/,
2011/CD
)/)
./.
====================
In/IN
particular/JJ
,/,
higher/JJR
copy/NN
numbers/NNS
of/IN
the/DT
kringle/JJ
(/(
IV/CD
)/)
domain/NN
in/IN
this/DT
protein/NN
are/VBP
associated/VBN
with/IN
lower/JJR
lipoprotein/NN
levels/NNS
(/(
van/NN
der/NN
Hoek/NN
et/FW
al./FW
,/,
1993/CD
)/)
./.
====================
Moreover/RB
,/,
Wong/JJ
et/FW
al/JJ
./.
====================
(/(
2007/CD
)/)
conducted/VBD
a/DT
CNV/NN
analysis/NN
using/VBG
a/DT
whole-genome/JJ
array/NN
comparative/JJ
genomic/JJ
hybridization/NN
(/(
aCGH/NN
)/)
./.
====================
Among/IN
the/DT
detected/VBN
CNVs/NNS
,/,
they/PRP
found/VBD
CNV/NN
loci/NNS
overlapping/VBG
LPA/NN
./.
====================
Association/NN
of/IN
BP/NN
with/IN
JAK2/NN
has/VBZ
also/RB
been/VBN
reported/VBN
./.
====================
Guilluy/RB
et/FW
al/JJ
./.
====================
(/(
2010/CD
)/)
showed/VBD
that/IN
inhibition/NN
of/IN
JAK2/NN
prevents/VBZ
angiotensin/NN
II-mediated/JJ
hypertension/NN
in/IN
wild-type/JJ
mice/NNS
./.
====================
In/IN
contrast/NN
with/IN
the/DT
results/NNS
of/IN
the/DT
association/NN
stage/NN
,/,
the/DT
two/CD
positive/JJ
findings/NNS
were/VBD
not/RB
confirmed/VBN
in/IN
the/DT
replication/NN
stage/NN
./.
====================
CNV/NN
loci/NNS
overlapping/VBG
LPA/NN
and/CC
JAK2/NN
were/VBD
observed/VBN
with/IN
nonsignificant/JJ
p-values/NNS
./.
====================
In/IN
the/DT
association/NN
stage/NN
,/,
other/JJ
well-established/JJ
risk/NN
loci/NNS
such/JJ
as/IN
ATP2B1/NN
,/,
FTO/NN
,/,
MC4R/NN
,/,
PPYR1/NN
,/,
ST7L-CAPZA1/NN
,/,
FIGNGRB14/NN
,/,
ENPEP/NNP
,/,
NPR3/NN
,/,
and/CC
TBX3/NN
that/IN
were/VBD
observed/VBN
in/IN
previous/JJ
GWAS/NNP
or/CC
CNV/NN
studies/NNS
(/(
Sha/NNP
et/FW
al./FW
,/,
2009/CD
;/:
Levy/NNP
et/FW
al./FW
,/,
2009/CD
;/:
Newton-Cheh/RB
et/FW
al./FW
,/,
2009/CD
;/:
Kato/RB
et/FW
al./FW
,/,
2011/CD
;/:
Frayling/VBG
et/FW
al./FW
,/,
2007/CD
;/:
Loos/NNP
et/FW
al./FW
,/,
2008/CD
;/:
Glessner/NNP
et/FW
al./FW
,/,
2010/CD
;/:
Dorajoo/RB
et/FW
al./FW
,/,
2011/CD
)/)
were/VBD
not/RB
observed/VBN
in/IN
our/PRP$
current/JJ
study/NN
./.
====================
There/EX
are/VBP
some/DT
potential/JJ
reasons/NNS
for/IN
why/WRB
these/DT
loci/NNS
were/VBD
not/RB
significantly/RB
observed/VBN
in/IN
our/PRP$
study/NN
./.
====================
First/RB
,/,
risk/NN
loci/NNS
affecting/VBG
hypertension/NN
may/MD
differ/VB
when/WRB
studying/VBG
CNVs/NNS
and/CC
SNPs/NNS
./.
====================
Alternatively/RB
,/,
rare/JJ
CNV/NN
variants/NNS
may/MD
affect/VB
the/DT
etiology/NN
of/IN
hypertension/NN
,/,
or/CC
hypertension/NN
may/MD
have/VB
few/JJ
common/JJ
risk/NN
alleles/NNS
that/IN
each/DT
has/VBZ
a/DT
relatively/RB
large/JJ
effect/NN
./.
====================
Finally/RB
,/,
some/DT
of/IN
the/DT
controls/NNS
may/MD
have/VB
been/VBN
misclassified/VBN
as/IN
cases/NNS
owing/VBG
to/TO
limitations/NNS
of/IN
current/JJ
CNV/NN
genotyping/VBG
technology/NN
./.
====================
Similar/JJ
results/NNS
supporting/VBG
our/PRP$
study/NN
have/VBP
been/VBN
reported/VBN
./.
====================
The/DT
WTCCC/NN
performed/VBN
an/DT
association/NN
study/NN
of/IN
common/JJ
CNVs/NNS
with/IN
eight/CD
common/JJ
diseases/NNS
including/VBG
hypertension/NN
using/VBG
the/DT
original/JJ
WTCCC/NN
study/NN
samples/NNS
(/(
WTCCC/NN
,/,
2010/CD
)/)
and/CC
identified/VBD
three/CD
CNV/NN
loci/NNS
that/IN
were/VBD
associated/VBN
with/IN
common/JJ
diseases/NNS
./.
====================
They/PRP
concluded/VBD
,/,
however/RB
,/,
that/DT
none/NN
of/IN
the/DT
three/CD
loci/NNS
was/VBD
believed/VBN
to/TO
be/VB
a/DT
functional/JJ
variant/JJ
and/CC
that/IN
common/JJ
CNVs/NNS
may/MD
not/RB
play/VB
a/DT
major/JJ
role/NN
in/IN
the/DT
genetic/JJ
basis/NN
of/IN
common/JJ
diseases/NNS
(/(
WTCCC/NN
,/,
2010/CD
)/)
./.
====================
Similar/JJ
to/TO
the/DT
conclusion/NN
of/IN
WTCCC/NN
,/,
few/JJ
association/NN
studies/NNS
of/IN
complex/NN
diseases/NNS
with/IN
CNVs/NNS
as/IN
newly/RB
discovered/VBN
genetic/JJ
markers/NNS
have/VBP
been/VBN
reported/VBN
./.
====================
For/IN
example/NN
,/,
Charchar/JJ
et/FW
al/JJ
./.
====================
(/(
2010/CD
)/)
conducted/VBD
a/DT
genomewide/JJ
survey/NN
of/IN
CNVs/NNS
in/IN
the/DT
spontaneously/RB
hypertensive/JJ
rat/NN
;/:
they/PRP
identified/VBD
and/CC
validated/VBD
16/CD
CNVs/NNS
associated/VBN
with/IN
the/DT
spontaneously/RB
hypertensive/JJ
phenotype/NN
./.
====================
In/IN
contrast/NN
with/IN
the/DT
association/NN
in/IN
the/DT
spontaneously/RB
hypertensive/JJ
rat/NN
,/,
Johnson/NN
et/FW
al/JJ
./.
====================
(/(
2009/CD
)/)
found/VBD
no/DT
association/NN
of/IN
CNVs/NNS
in/IN
BMPR2/NN
with/IN
pulmonary/JJ
arterial/JJ
hypertension/NN
in/IN
human/JJ
./.
====================
Our/PRP$
data/NNS
are/VBP
consistent/JJ
with/IN
those/DT
of/IN
the/DT
WTCCC/NN
CNV/NN
study/NN
,/,
which/WDT
suggests/VBZ
that/IN
functional/JJ
variants/NNS
and/CC
common/JJ
CNVs/NNS
may/MD
not/RB
play/VB
a/DT
major/JJ
role/NN
in/IN
the/DT
genetic/JJ
basis/NN
of/IN
common/JJ
diseases/NNS
(/(
WTCCC/NN
,/,
2010/CD
)/)
./.
====================
Moreover/RB
,/,
the/DT
absence/NN
of/IN
a/DT
positive/JJ
result/NN
in/IN
the/DT
rep/NN
lication/NN
stage/NN
of/IN
our/PRP$
study/NN
may/MD
be/VB
due/JJ
to/TO
the/DT
frequency/NN
of/IN
occurrence/NN
./.
====================
That/DT
is/VBZ
,/,
because/IN
recurrence/NN
rates/NNS
of/IN
uncommon/JJ
(/(
or/CC
less/RBR
common/JJ
)/)
CNV/NN
loci/NNS
with/IN
frequencies/NNS
of/IN
1∼5/CD
%/NN
may/MD
vary/VB
between/IN
populations/NNS
,/,
our/PRP$
two/CD
positive/JJ
findings/NNS
(/(
2.9/CD
%/NN
for/IN
LPA/NN
and/CC
1.9/CD
%/NN
for/IN
JAK2/NN
)/)
may/MD
not/RB
be/VB
replicated/VBN
in/IN
the/DT
association/NN
stage/NN
./.
====================
Alternatively/RB
,/,
similar/JJ
to/TO
the/DT
association/NN
stage/NN
,/,
the/DT
limitation/NN
of/IN
platform/NN
resolution/NN
may/MD
lead/VB
to/TO
replication/NN
failure/NN
./.
====================
Consequently/RB
,/,
to/TO
resolve/VB
obstacles/NNS
underlying/VBG
a/DT
CNV/NN
association/NN
study/NN
such/JJ
as/IN
the/DT
complexity/NN
of/IN
the/DT
genetic/JJ
architecture/NN
for/IN
hypertension/NN
and/CC
the/DT
limitation/NN
of/IN
the/DT
current/JJ
CNV/NN
genotyping/VBG
techniques/NNS
,/,
a/DT
more/RBR
comprehensive/JJ
study/NN
with/IN
a/DT
higher-resolution/JJ
platform/NN
will/MD
be/VB
necessary/JJ
to/TO
identify/VB
genetic/JJ
variants/NNS
that/IN
affect/VBP
hypertension/NN
./.
====================
There/EX
are/VBP
some/DT
limitations/NNS
associated/VBN
with/IN
our/PRP$
approach/NN
./.
====================
As/IN
we/PRP
used/VBD
the/DT
Affymetrix/JJ
5.0/CD
for/IN
the/DT
replication/NN
stage/NN
,/,
we/PRP
could/MD
not/RB
address/VB
whether/IN
two/CD
signals/NNS
were/VBD
not/RB
replicated/VBN
or/CC
were/VBD
false/RB
positive/JJ
signals/NNS
./.
====================
Therefore/RB
,/,
validation/NN
experiment/NN
such/JJ
as/IN
quantitative/JJ
PCR/NN
(/(
qPCR/NN
)/)
is/VBZ
needed/VBN
for/IN
the/DT
accurate/JJ
analysis/NN
./.
====================
In/IN
conclusion/NN
,/,
our/PRP$
result/NN
is/VBZ
consistent/JJ
with/IN
that/DT
of/IN
the/DT
WTCCC/NN
CNV/NN
study/NN
./.
====================
Thus/RB
,/,
our/PRP$
study/NN
confirmed/VBD
the/DT
conclusion/NN
of/IN
WTCCC/NN
CNV/NN
study/NN
suggesting/VBG
no/DT
association/NN
with/IN
complex/NN
traits/VBZ
./.
====================
In/IN
addition/NN
,/,
this/DT
is/VBZ
the/DT
first/JJ
CNV/NN
association/NN
to/TO
examine/VB
the/DT
contribution/NN
of/IN
CNVs/NNS
to/TO
hypertension/NN
in/IN
a/DT
Korean/JJ
population/NN
./.
====================
Therefore/RB
,/,
our/PRP$
study/NN
will/MD
also/RB
provide/VBP
new/JJ
insight/NN
into/IN
the/DT
genetics/NNS
associated/VBN
with/IN
complex/NN
traits/VBZ
having/VBG
CNVs/NNS
in/IN
the/DT
Korean/JJ
population/NN
./.
====================
Supplementary/JJ
data/NNS
including/VBG
a/DT
figure/NN
and/CC
two/CD
tables/NNS
can/MD
be/VB
found/VBN
with/IN
this/DT
article/NN
online/JJ
at/IN
http/NN
:/:
//www/JJ
./.
====================
genominfo/RB
./.
====================
org/html/UploadFile/article2_201112_SP/NN
./.
====================
pdf/IN
./.
====================
This/DT
work/NN
was/VBD
supported/VBN
by/IN
intramural/JJ
grant/JJ
from/IN
the/DT
Korea/NN
National/JJ
Institute/JJ
of/IN
Health/NN
(/(
2008-N7300200/CD
)/)
and/CC
grants/NNS
from/IN
the/DT
Korea/NN
Centers/NNS
for/IN
Disease/NN
Control/NN
and/CC
Prevention/NN
(/(
4845-301/CD
,/,
4851-302/CD
,/,
4851-307/CD
)/)
./.
====================
